Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $29.95 million. The enterprise value is $10.11 million.
Important Dates
The next confirmed earnings date is Thursday, November 7, 2024, before market open.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 5.35 million shares outstanding. The number of shares has increased by 1.57% in one year.
| Current Share Class | 5.35M |
| Shares Outstanding | 5.35M |
| Shares Change (YoY) | +1.57% |
| Shares Change (QoQ) | -0.25% |
| Owned by Insiders (%) | 2.91% |
| Owned by Institutions (%) | 10.00% |
| Float | 5.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.71 |
| Forward PS | 25.95 |
| PB Ratio | 1.53 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.56, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.56 |
| Quick Ratio | 12.40 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -34.12% and return on invested capital (ROIC) is -24.15%.
| Return on Equity (ROE) | -34.12% |
| Return on Assets (ROA) | -22.67% |
| Return on Capital (ROIC) | -24.15% |
| Revenue Per Employee | $282,408 |
| Profits Per Employee | -$499,308 |
| Employee Count | 17 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $1,236 in taxes.
| Income Tax | 1,236 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +119.23% in the last 52 weeks. The beta is 1.19, so Lipocine's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | +119.23% |
| 50-Day Moving Average | 4.86 |
| 200-Day Moving Average | 5.24 |
| Relative Strength Index (RSI) | 56.35 |
| Average Volume (20 Days) | 24,714 |
Short Selling Information
The latest short interest is 107,537, so 2.01% of the outstanding shares have been sold short.
| Short Interest | 107,537 |
| Short Previous Month | 110,811 |
| Short % of Shares Out | 2.01% |
| Short % of Float | 2.07% |
| Short Ratio (days to cover) | 2.80 |
Income Statement
In the last 12 months, Lipocine had revenue of $4.80 million and -$8.49 million in losses. Loss per share was -$1.61.
| Revenue | 4.80M |
| Gross Profit | 4.80M |
| Operating Income | -9.71M |
| Pretax Income | -8.49M |
| Net Income | -8.49M |
| EBITDA | -9.67M |
| EBIT | -9.71M |
| Loss Per Share | -$1.61 |
Full Income StatementBalance Sheet
The company has $22.55 million in cash and $245,384 in debt, giving a net cash position of $22.30 million or $4.17 per share.
| Cash & Cash Equivalents | 22.55M |
| Total Debt | 245,384 |
| Net Cash | 22.30M |
| Net Cash Per Share | $4.17 |
| Equity (Book Value) | 21.21M |
| Book Value Per Share | 3.97 |
| Working Capital | 21.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.72 million and capital expenditures -$9,167, giving a free cash flow of -$4.73 million.
| Operating Cash Flow | -4.72M |
| Capital Expenditures | -9,167 |
| Free Cash Flow | -4.73M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -202.18% and -176.80%.
| Gross Margin | 100.00% |
| Operating Margin | -202.18% |
| Pretax Margin | -176.78% |
| Profit Margin | -176.80% |
| EBITDA Margin | -201.50% |
| EBIT Margin | -202.18% |
| FCF Margin | -98.48% |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.57% |
| Shareholder Yield | -1.57% |
| Earnings Yield | -26.19% |
| FCF Yield | -14.59% |
Analyst Forecast
The average price target for Lipocine is $10.00, which is 78.57% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 78.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 0.0588235:1.
| Last Split Date | May 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0588235:1 |
Scores
Lipocine has an Altman Z-Score of -4.77 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.77 |
| Piotroski F-Score | 2 |